Dr. Tzu-Fei Wang
Dr. Tzu-Fei Wang
Associate Professor, Department of Medicine, Division of Hematology, University of Ottawa
Associate Scientist, Ottawa Hospital Research Institute



Tzu-Fei Wang, MD, MPH is a hematologist and an associate professor in the Division of Hematology, Department of Medicine at the University of Ottawa and the Ottawa Hospital and an associate scientist at the Ottawa Hospital Research Institute. Her main areas of clinical and research interest include clinical research for the optimal prevention and treatment strategies for patients with cancer-associated thrombosis, drug-drug interactions with anticoagulants, and obesity related thromboembolism.

Selected publications:

  1. Wang TF, Clarke A, Awan AA, Tanuseputro P, Carrier M, Sood MM. Hemorrhage risk in direct oral anticoagulant users receiving tamoxifen versus aromatase inhibitors for breast cancer. JAMA Network Open. 2022 Jun 1;5(6):e2219128. doi: 10.1001/jamanetworkopen.2022.19128. [PMID: 35763294].
  2. Wang TF, Mallick R, Carrier M, Wells PS. Safety and efficacy of apixaban thromboprophylaxis in ambulatory cancer patients according to renal function: A subgroup analysis of the AVERT trial. Thromb Res. 2022 Jan 31;211:85-87. doi: 10.1016/j.thromres.2022.01.022. Online ahead of print. [PMID: 35124234].
  3. Wang TF, Carrier M, Fournier K, Siegal DM, Le Gal G, Delluc A. Oral anticoagulant use in patients with morbid obesity: A systematic review and meta-analysis. Thromb Haemost. 2021 Aug 16. doi: 10.1055/a-1588-9155. [PMID: 34399433].
  4. Wang TF, Baumann Kreuziger L, Leader A, Spectre G, Lim MY, Gahagan A, Gangaraju R, Sanfilippo KM, Mallick R, Zwicker JI, Carrier M. Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies – TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. J Thromb Haemost. 2021 Aug;19(8):2068-2081. doi: 10.1111/jth.15367. [PMID: 34327825].
  5. Caiano L, Carrier M, Marshall A, Young AM, Ageno W, Delluc A, Wang TF. Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost. 2021 Jun 23. doi: 10.1111/jth.15435. Online ahead of print. [PMID: 34161655].
  6. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia DA, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine. 2018 Feb 15; 378(7):615- 624. [PMID: 29231094].

Research interests

  • Cancer associated thrombosis
  • Venous Thromboembolism
  • Systematic Reviews and Meta-analyses
  • Clinical Trials